Lrpprc, or leucine-rich pentatricopeptide repeat-containing protein, is a member of the pentatricopeptide repeat (PPR) family. It binds to DNA, RNA, and proteins to regulate transcription and translation, and is involved in multiple biological processes such as energy metabolism, maturation and export of nuclear mRNA [2,6]. It also plays a role in maintaining normal mitochondrial translation in mammals, as it forms a complex with SLIRP in the mitochondrial matrix, which is essential for the life cycle of most mitochondrial mRNAs [5].

In disease-related studies, knockdown of Lrpprc in RAW 264.7 cells decreased foam cell formation in atherosclerosis, suggesting that Lrpprc promotes foam cell formation by inhibiting autophagy [4]. In lung cancer, Lrpprc forms a feedback loop with CDK6, promoting resistance to CDK4/6 inhibition. Gossypol acetate, a degrader of Lrpprc, enhances the sensitivity to CDK4/6 inhibitors [1]. In triple-negative breast cancer, Lrpprc promotes glycolysis by stabilizing LDHA mRNA, and knockdown of Lrpprc plus glutamine inhibitor induces synthetic lethality [3]. In ovarian cancer, HAPSTR1 binds to Lrpprc, suppresses its ubiquitination, and promotes tumor progression, while Lrpprc knockdown reverses these effects [7].

In conclusion, Lrpprc is a multifunctional protein involved in various biological processes and diseases. Studies using loss-of-function models, such as knockdown experiments, have revealed its roles in cancer, atherosclerosis, and other disease conditions, highlighting its potential as a biomarker and therapeutic target.